Nov 30, 2021 / 03:30PM GMT
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
All right. Welcome, everyone. It's Josh Schimmer from the Evercore ISI Biotech team. Pleased to welcome Brett Monia from Ionis Pharmaceuticals. I love Ionis. You've got such a powerful platform, such incredible biologists, and you're forging new ground into biology. And forging new ground comes with risk and some things work and some things don't work and you learn along the way. And Ionis is always patient with a little bit of my snarkier or cattiness when things don't go as well as planned. But there's always something exciting to talk about.
Questions and Answers:
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity AnalystSo thanks for joining us. Maybe we can start with tofersen. It's kind of one of the recent updates that didn't quite hit the mark, but it really did look like it came close. What are we -- what are you thinking in terms of the current data set, whether there's more we